Vedanta Biosciences Raises $60 Million to Advance Phase 3 VE303 Program

Vedanta Biosciences has secured $60 million in new funding to support the continued development of its lead microbiome-based therapy, VE303,... Read More

The post Vedanta Biosciences Raises $60 Million to Advance Phase 3 VE303 Program appeared first on citybiz.